LudwigJViggianoTRMcGillDBOttBJ. Non-alcoholic steatohepatitis—Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
2.
OngJPYounossiZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007;11(1):1-16.
3.
FraserALongneckerMPLawlorDA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology. 2007;133:1814-1820.
4.
BrowningJDSzczepaniakLSDobbinsR. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
5.
VerrijkenAFrancqueSMertensITalloenMPeifferFVan GaalL. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int J Obes (Lond). 2010;34:899-907.
6.
SchwimmerJBPardeePELavineJEBlumkinAKCookS. Cardiovascular risk factors and metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277-283.
7.
MarchesiniGBabiniM. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol. 2006;54:229-239.
8.
WilliamsCDStengelJAsikeMI. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131.
9.
LoombaRSirlinCBSchwimmerJBLavineJE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50:1282-1293.
10.
WanlessIRLentzJS. Fatty liver hepatitis (steatohepatitis) and obesity—an autopsy study with analysis of risk-factors. Hepatology. 1990;12:1106-1110.
11.
WhiteDLKanwalFEl-SeragHB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342.e2-1359.e2.
12.
AlyFZKleinerDE. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol. 2011;18:294-300.
13.
MandatoCLucarielloSLicenziatiMR. Metabolic, hormonal, oxidative, and inflammatory factors in pediatric obesity-related liver disease. J Pediatr. 2005;147:62-66.
14.
CusiK. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711.e6-725.e6.
15.
ChitturiSGeorgeJ. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep. 2003;5:18-25.
16.
BremerAAMietus-SnyderMLustigRH. Toward a unifying hypothesis of metabolic syndrome. Pediatrics. 2012;129:557-570.
17.
RomeoSKozlitinaJXingC, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461-1465.
18.
HuangYHeSLiJZ. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010;107:7892-7897.
YounossiZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28:2-12.
21.
D’AdamoECaliAMWeissR. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care. 2010;33:1817-1822.
22.
SchwimmerJBPardeePELavineJEBlumkinAKCookS. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277-283.
23.
AlkhouriNDe VitoRAlisiA. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol. 2012;57:1312-1318.
24.
KleinerDEBruntEMVan NattaM. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
25.
SchwimmerJBBehlingCNewburyR. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42:641-649.
26.
GuturuPDuchiniA. Etiopathogenesis of nonalcoholic steatohepatitis: role of obesity, insulin resistance and mechanisms of hepatotoxicity. Int J Hepatol. 2012;2012::212865.
27.
VuppalanchiRChalasaniN. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306-317.
28.
AbdelmalekMFSuzukiAGuyC. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961-1971.
29.
ElliottSSKeimNLSternJSTeffKHavelPJ. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr. 2002;76:911-922.
30.
ToshimitsuKMatsuuraBOhkuboI. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007;23:46-52.
31.
HazlehurstJMTomlinsonJW. Non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol. 2013;169:R27-R37.
DeboerMDWienerRCBarnesBHGurkaMJ. Ethnic differences in the link between insulin resistance and elevated ALT. Pediatrics. 2013;132:e718-e726.
36.
SchwimmerJBDeutschRKahenTLavineJEStanleyCBehlingC. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388-1393.
37.
GuerreroRVegaGLGrundySMBrowningJD. Ethnic differences in hepatic steatosis: an insulin resistance paradox?Hepatology. 2009;49:791-801.
38.
CaldwellSHHespenheideEE. Subacute liver failure in obese women. Am J Gastroenterol. 2002;97:2058-2062.
39.
BambhaKBeltPAbrahamM. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55:769-780.
40.
LomonacoROrtiz-LopezCOrsakB. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54:837-845.
41.
SchwimmerJBMcGrealNDeutschRFinegoldMJLavineJE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics. 2005;115:e561-e565.
42.
DabeleaDBellRAD’AgostinoRBJr. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716-2724.
43.
DeBoerMDGurkaMJSumnerAE. Diagnosis of the metabolic syndrome is associated with disproportionately high levels of high-sensitivity C-reactive protein in non-Hispanic black adolescents: an analysis of NHANES 1999-2008. Diabetes Care. 2011;34:734-740.
44.
DeBoerMD. Ethnicity, obesity and the metabolic syndrome: implications on assessing risk and targeting intervention. Expert Rev Endocrinol Metab. 2011;6:279-289.
45.
DeBoerMDDongLGurkaMJ. Racial/ethnic and sex differences in the ability of metabolic syndrome criteria to predict elevations in fasting insulin levels in adolescents. J Pediatr. 2011;159:975.e3-981.e3.
46.
DeBoerMDGurkaMJ. Low sensitivity for the metabolic syndrome to detect uric acid elevations in females and non-Hispanic-black male adolescents: an analysis of NHANES 1999-2006. Atherosclerosis. 2012;220:575-580.
47.
DasarathySDasarathyJKhiyamiAJosephRLopezRMcCulloughAJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061-1067.
48.
StraussSGavishEGottliebPKatsnelsonL. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol. 2007;189:W320-W323.
49.
PacificoLCelestreMAnaniaCPaolantonioPChiesaCLaghiA. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr. 2007;96:542-547.
50.
YonedaMMawatariHFujitaK. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40:371-378.
51.
GuhaINParkesJRoderickP. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47:455-460.
52.
AfdhalNH. Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?JAMA. 2012;308:608-616.
53.
StewartKELevensonJL. Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease. Clin Liver Dis. 2012;16:615-629.
54.
BellentaniSBedogniGMiglioliL. Natural history of chronic liver disease in the Dionysos cohort. Hepatology. 2008;48:1130A.
55.
VajroPFontanellaAPernaCOrsoGTedescoMDevincenzoA. Persistent hyperaminotransferasemia resolving after weight-reduction in obese children. J Pediatr. 1994;125:239-241.
56.
FranzeseAVajroPArgenzianoA. Liver involvement in obese children—ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci. 1997;42:1428-1432.
57.
NobiliVMarcelliniMDevitoR. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44:458-465.
58.
SanyalAJChalasaniNKowdleyKV. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.
59.
LavineJESchwimmerJBVan NattaML. Effect of vitamin e or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659-1668.
60.
DohilRSchmeltzerSCabreraBL. Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33:1036-1044.
61.
JanczykWSochaPLebensztejnD. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr. 2013;13:85.
62.
RatziuVGiralPJacqueminetS. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology. 2008;135:100-110.
63.
MannucciEMonamiMMarchionniN. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007;357:938-938.
ChalasaniNYounossiZLavineJE. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-2023.
66.
BarlowSE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(suppl 4):S164-S192.
67.
FeldsteinAECharatcharoenwitthayaPTreeprasertsukSBensonJTEndersFBAnguloP. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538-1544.
68.
KrebsNFHimesJHJacobsonDNicklasTAGuildayPStyneD. Assessment of child and adolescent overweight and obesity. Pediatrics. 2007;120(suppl 4):S193-S228.
69.
RileyMRBassNMRosenthalPMerrimanRB. Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. J Pediatr. 2005;147:839-842.
70.
VajroPLentaSSochaP. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012;54:700-713.
71.
SchwimmerJBDunnWNormanGJ. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology. 2010;138:1357-1364.
72.
SchwimmerJBNewtonKPAwaiHI. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:1267-1277.
